Drugs /
ruxolitinib
Back to Drugs List
Associated Genetic Biomarkers
Overview
Clinical Trials
Ruxolitinib has been investigated in 64 clinical trials, of which 55 are open and 9 are closed. Of the trials investigating ruxolitinib, 17 are phase 1 (16 open), 14 are phase 1/phase 2 (11 open), 24 are phase 2 (19 open), 1 is phase 2/phase 3 (1 open), and 8 are phase 3 (8 open).
KMT2A Fusion, KMT2A-AFF1 Fusion, and KMT2A-ELL Fusion are the most frequent biomarker inclusion criteria for ruxolitinib clinical trials.
Primary myelofibrosis, myelofibrosis, and myelofibrosis transformation in essential thrombocythemia are the most common diseases being investigated in ruxolitinib clinical trials [2].
Drug Details
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].
2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.